DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma

SAN DIEGO, Dec. 1, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term results from the Phase 3 ALCYONE study showing that the addition of DARZALEX® (daratumumab) to bortezomib, melphalan and prednisone (VMP) continued to demonstrate...

from PR Newswire: https://ift.tt/2SovRKm